Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in osteoarthritis.

Bob H Sun1, Christopher W Wu, Kenneth C Kalunian

  • 1Center of Innovative Therapies, University of California at San Diego, 9320 Campus Point Drive, Suite 225, La Jolla, CA 92037-0943, USA.

Rheumatic Diseases Clinics of North America
|March 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus.

ACR open rheumatology·2026
Same author

Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression.

Annals of the rheumatic diseases·2026
Same author

A population-scale atlas of blood and tissue in lupus nephritis.

bioRxiv : the preprint server for biology·2026
Same author

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

High interferon response signatures in SLE patient leukocytes are associated with increased transposable element expression in gene introns and intergenic regions.

Mobile DNA·2025
Same journal

Rheumatology at the Threshold of Artificial Intelligence.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence Regulation in the United States: Current Landscape and Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

The Role of Artificial Intelligence in Medical Education and Training: Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Sources of Bias in Clinical Artificial Intelligence and Applications in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Toward Bridging the Gap from Artificial Intelligence in Clinical Research to Clinical Practice in Rheumatology: The Mayo Experience.

Rheumatic diseases clinics of North America·2026
See all related articles

Osteoarthritis (OA) is a growing public health concern, impacting millions globally. Current treatments only manage symptoms, highlighting the urgent need for disease-modifying drugs to halt OA progression.

Area of Science:

  • Orthopedics and Rheumatology
  • Gerontology
  • Epidemiology

Background:

  • Osteoarthritis (OA) presents a significant societal burden, comparable to ischemic heart disease.
  • Aging populations and rising obesity rates are projected to increase OA's impact.
  • Existing OA treatments primarily alleviate pain and improve function, without affecting disease progression.

Purpose of the Study:

  • To underscore the critical need for developing disease-modifying osteoarthritis drugs (DMOADs).
  • To explore recent advancements in understanding OA pathophysiology.
  • To assess the potential for achieving disease modification in OA treatment.

Main Methods:

  • Literature review of current OA impact and treatment limitations.
  • Analysis of epidemiological trends related to aging and obesity.

Related Experiment Videos

  • Review of recent research in OA pathophysiology.

    • Main Results:

    • OA's societal and economic impact is substantial and growing.
    • Current therapeutic options for OA are insufficient for disease modification.
    • Advances in understanding OA mechanisms offer hope for future DMOADs.

    Conclusions:

    • Developing DMOADs is a paramount research challenge.
    • New insights into OA pathophysiology suggest disease modification is achievable.
    • Addressing OA progression is essential for public health.